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CLINICAL INVESTIGATION
Intraperitoneal deferoxamine therapy for iron overload in
children undergoing CAPD
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Department ofPediatrics and Radiology, Indiana Uni'ersitv Medical Center, Indianapolis, Indiana, USA
Intraperitoneal deferoxamine therapy for iron overload in children
undergoing CAPD. We treated three children with renal failure and
chronic iron overload with intraperitoneal deferoxamine therapy. Each
child had an elevated serum ferritin level, a dense liver as measured by
computerized tomography (Hounsfield Units) and one had dialysis
related porphyria cutanea tarda. Deferoxamine therapy (10 to 17.5 mgI
kg) was given in the overnight exchange for three to six months. Prior
to therapy, iron was not detected in the dialysate; during the course of
therapy, daily dialysate iron removal averaged 5652 tg, 2241 g and
4028 g in the three children. The serum ferritin level fell during the
course of therapy in two children who were estimated to be in negative
iron balance, and was unchanged in the third who was estimated to be
in positive iron balance due to frequent transfusions. In 10 children with
chronic renal failure, there was a linear correlation (r = 0.855; P <0.01)
between the serum ferritin and the liver density, suggesting that an
increased serum ferritin correlates with hepatic iron content. interest-
ingly, in each of the three children who received deferoxamine therapy,
the liver density increased during therapy regardless of the estimated
iron balance and the change in the serum ferritin level. We conclude
that intraperitoneal deferoxamine therapy results in substantial iron
losses in peritoneal dialysate, can result in negative iron balance but, in
this study, did not result in lower liver iron content as measured by
density on computerized tomography scan.
Repeated blood transfusions for severe anemia in patients
with chronic renal failure can result in substantial morbidity
from iron overload. Chronic iron intoxication can result in
cardiac failure, hepatic damage and endocrine alterations in-
cluding pancreatic islet cell, thyroid, parathyroid, and adrenal
dysfunction [1—3]. Massive soft tissue iron deposits in the liver,
spleen, pancreas, skeletal and cardiac muscles have been
detected in patients with chronic renal failure who received
multiple transfusions [4, 5]. In addition, iron has been detected
at the mineralization front in bone in patients with chronic renal
failure [5, 6]. Adults and children who express HLA antigens
which are associated with idiopathic hemochromatosis (A3, B7
or B14) may have an increased risk to develop iron overload
following transfusion [7, 8].
Deferoxamine therapy in transfusion dependent children with
red blood cell dyscrasias can result in negative iron balance,
prevent cardiac dysfunction and reduce serum ferritin levels [9,
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10]. In patients with renal failure, intravenous and intraperito-
neal deferoxamine therapy has been used to treat iron overload
and aluminum intoxication [11—13]. Studies by Falk et al
demonstrated that intraperitoneal deferoxamine therapy was an
efficient means of iron removal in a patient maintained with
continuous ambulatory peritoneal dialysis (CAPD) [11]. We
report the response to intraperitoneal deferoxamine therapy in
three children with iron overload; one of these children had
dialysis related porphyria cutanea tarda [14—16].
Methods
Patients
Beginning in January, 1985, we obtained a serum ferritin level
every three months in children undergoing dialysis at our
hospital to monitor for the development of iron overload.
Children with chronic renal failure and a serum ferritin level
greater than 2000 ng/ml (normal less than 250 nglml) in the
absence of liver disease, infection or inflammation were con-
sidered eligible for deferoxamine therapy. A ferritin level of
2000 nglml was arbitrarily chosen as a level to reflect high iron
stores. Only children who were not likely to receive a kidney
transplant in the near future were considered. The study
protocol was approved by the Indiana University Committee
for protection of human subjects. Of forty-one children who
received chronic dialysis therapy at our hospital since 1985, a
serum ferritin level was obtained on thirty-five. Five children
had a serum ferritin greater than 2000 ng/ml on more than one
occasion. One child was ineligible due to a chronic exit-site
infection and another could not receive intraperitoneal therapy
as ultrafiltration failure necessitated hemodialysis therapy. The
three other children with serum ferritin levels greater than 2000
ng/ml elected to participate in the study.
Patient one is an 18-year-old boy with chronic renal failure as
a result of obstructive uropathy and renal dysplasia associated
with the prune belly syndrome. He required multiple transfu-
sions prior to the initiation of dialysis therapy in June, 1985.
Following nephrectomy in preparation for a kidney transplant,
his transfusion requirement increased to two to three units of
frozen packed red blood cells per month. A cadaveric renal
transplant performed in January, 1986, was removed nine
months later due to chronic rejection. During this interval, the
patient developed bullous skin lesions typical of porphyria
cutanea tarda in sun exposed areas. CAPD was initiated and he
again required frequent blood transfusions. By December,
1986. he had received 42 units of packed cells (equivalent to
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8400 mg iron) and his serum ferritin level was 2935 ng/ml. When
he had several inflammed skin lesions, his serum ferritin level
was 6250, 7874 and 4163 ng/ml on three separate occasions. in
April, 1987, intraperitoneal therapy with deferoxamine (10 mgI
kg in each overnight bag) was begun. Following the initiation of
therapy, new bulious lesions did not occur while the old lesions
slowly healed. The markedly elevated serum ferritin (a result of
chronic iron overload and inflammatory skin lesions) declined
to 2809 and 3758 ng/ml during the first months of therapy. in
May 1987, he developed peritonitis and deferoxamine therapy
was temporarily discontinued. While not receiving deferoxa-
mine, the patient developed numerous new bullous lesions
which resoived when therapy was resumed. During July, 1987,
the patient participated in several outdoor activities and he
again developed lesions of porphyria cutanea tarda in sun
exposed skin while receiving 10 mg/kg/day deferoxamine. No
new lesions occurred when the dose of deferoxamine was
increased to 17.5 mg/kg in each overnight exchange. Deferoxa-
mine therapy was discontinued in September, 1987, when he
developed peritonitis. After therapy was stopped in October,
1987, the serum ferritin level was 2634 ng/ml. During the six
month course of deferoxamine therapy he received four units of
frozen packed red blood cells (800 mg iron). Therapy was
resumed in the spring of 1988 and in June, 1988, he was
transferred to hemodialysis due to Pseudomonas aeruginosa
peritonitis. At that time, fractionated plasma porphyrins were
uroporphyrins 237 tg/dl, heptacarboxyporphyrins 140 ig/dl,
hexacarboxyporphyrins 21 g/dl, pentacarboxyporphyrins less
than I g/di, coproporphyrins 2 g/dl, and protoporphyrins less
than I g/dl (normal for each, less than I sg/dl).
Patient two is a 15-year-old girl with chronic renal failure as
the result of the hemolytic-uremic syndrome; she has been
maintained on CAPD since age 9 and has required multiple
transfusions. During this time period, she received one living
related and two cadaveric renal transplants which were each
rejected. By February, 1987, she had received 69 units of
packed red blood cells (equivalent to 13,800mg of iron) and her
serum ferritin was 2114 ng/mI. Intraperitoneal deferoxamine
therapy (10 mg/kg in each overnight bag) was begun and then
stopped six months later when her serum ferritin had declined
to 1266 ng/ml. For reasons that are unclear, she only required
two units of frozen packed red blood cells approximately (400
mg iron) during the course of deferoxamine therapy.
The third patient is a 16-year-old boy with chronic renal
failure as a result of Alport's syndrome. He underwent bilateral
nephrectomy in October, 1983 and a living related renal trans-
plant in January, 1984. Following a complicated post-transplant
course, he underwent graft nephrectomy and he was started on
CAPD in June, 1984. He required two to three units of frozen
packed red blood cells per month for severe anemia. By
October, 1985, he had received 58 units of packed red blood
cells (equivalent to 11,600 mg iron) and his serum ferritin had
increased to 3049 ng/ml. Intraperitoneal deferoxamine therapy
(10 mg/kg in each overnight bag) was begun and continued until
February, 1986, when he underwent elective repair of choanal
stenosis from a remote tonsillectomy and adenoidectomy. Dur-
ing the three month course of therapy, he required six units of
frozen packed red blood cells (approximately 1200 mg iron). He
received six additional units of packed red blood cells before a
post-therapy CT scan could be performed.
Study protocol
Prior to therapy, the following studies were obtained: CBC,
electrolytes, BUN, creatinine, calcium, phosphorus, SGOT,
SGPT, PT, PTT, total protein, albumin, iron, total iron binding
capacity, ferritin, transferrin, fasting blood sugar, copper, alu-
minum, zinc, parathyroid hormone, echocardiogram, and oph-
thalmologic exam. In addition each patient underwent a liver
CT scan for determination of liver density as an estimation of
iron content. All of the CT scans were performed on the same
CT scanning unit (a Techicare 1024 CT Scanner). A one
centimeter thick slice was obtained through the midpart of the
liver using a KVP of 130. Liver intensity in Hounsfield units
was measured by placing a I cm diameter region of interest
cursor at three points on the liver, avoiding blood vessels and
ducts, and using the mean of three readings. This method of
estimating iron density has been found to correlate with hepatic
iron content and serum ferritin values [17, 18]. As these patients
were undergoing peritoneal dialysis, percutaneous liver biop-
sies to precisely quantitate iron content were not performed due
to the potential complication of intraperitoneal hemorrhage.
Seven additional children who were not candidates for defero-
xamine therapy underwent a liver CT scan to determine the
relationship between serum ferritin and liver density.
Deferoxamine therapy was initiated at a dose of 10 mg/kg
while the patient was hospitalized. This starting dose was
chosen as it was slightly lower than doses previously shown
effective for iron and aluminum removal [11—13]. To minimize
the potential for contamination and the development of perito-
nitis, deferoxamine was added to one exchange per day, usually
the overnight bag. Blood was obtained for iron content at 4, 8,
12, and 24 hours after the first intraperitoneal deferoxamine
infusion. Dialysate effluent was also collected and iron removal
determined. Ferritin, iron, chelated iron and 24-hour dialysate
iron content were determined once or twice a month and liver
CT scan for liver density every three to six months. None of the
patients received oral iron therapy during the study. Dietary
iron was not considered when calculating the estimated iron
balance.
Biochemical determinations
Iron was determined by a colorimetric method on a Dupont
aca spectrophotometer (DuPont Instruments, Willington, Del-
aware, USA). To determine the total iron content in samples
that contained deferoxamine, serum and dialysate samples were
treated with thioglycolic acid [191. This method of measuring
iron in samples that contain deferoxamine has been described in
detail by our laboratory and correlates very closely with atomic
absorption spectroscopy (95.5 8.0%, N = 8) [19]. Recovery
of exogenous iron added to dialysate containing deferoxamine
and treated with thioglycolic acid was 99%. Serum ferritin
levels were determined by enzyme-immunoassay. Fractionated
plasma porphyrins on patient one were determined by high
pressure liquid chromatography by Mayo Medical Laborato-
ries.
HLA antigens
HLA antigen typing was performed by the Indiana University
tissue typing laboratory with a microlymphocytotoxic assay as
a part of the patients' transplant evaluation.
in the serum ferritin level during the course of therapy in these
two patients. In contrast, patient 3 received 1200 mg of iron
from blood transfusions during the three month course of
deferoxamine therapy while dialysate iron losses were esti-
mated at 368 mg, suggesting that he was in positive iron
balance. This patient's serum ferritin did not decline during
therapy. During the course of therapy, the amount of iron
removed did not trend downwards in the three children.
Liver density determinations
Among the 10 children who underwent a liver CT scan, there
was a linear correlation (r = 0.855; P < 0.01) between the serum
ferritin and the liver density, suggesting that an increased serum
ferritin level correlates with hepatic iron content (Fig. 2).
Although patients one and two were estimated to be in negative
iron balance and patient 3 in positive iron balance, the liver
density of each patient was increased following the completion
of therapy suggesting that liver iron content was not reduced
(Table I).
HLA antigens
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Fig. 1. Total serum iron at 4, 8, 12 and 24 hours following the first
intraperitoneal dose of deferoxamine. Peak serum total iron levels were
reached at 12 hours in patients one and two and at 24 hours in patient
3.
Statistical analysis
Linear regression analysis was used to evaluate for a corre-
lation between the serum ferritin level and the liver density
measured by computerized tomographic scan. Among the chil-
dren who received deferoxamine therapy, only the values prior
to therapy were included in this analysis.
Results
Iron removal studies
Following the first intraperitoneal dose of deferoxamine, the
total serum iron level increased in each patient beginning at four
hours, reaching the highest level at 12 hours in patient 2 and 3,
and at 24 hours in patient I (Fig. 1) demonstrating absorption of
deferoxamine from the peritoneal cavity and mobilization of
iron from body stores. In patients 2 and 3, the serum iron level
remained elevated (131 and 144%) above baseline values at 24
hours. The iron level was less than 10 tg/dl in spent dialysate
prior to deferoxamine therapy. The amount of iron removed in
the 24 hours following the infusion of the first intraperitoneal
dose of deferoxamine was 2935, 1016, and 3057 g in patients 1,
2, and 3, respectively. During the course of therapy, daily iron
removal averaged 5652 g (range 3085 to 8045 ig; N = 6) in
patient one, 2241 tg (range 1912 to 2852 g; N = 6) in patient
two and 4028 zg (range, 2910 to 5583 Lg; N = 5) in patient three
(Table 1). Thus, during the six months of therapy iron removal
in peritoneal dialysate could be estimated at 1,031 mg in patient
one and 408 mg in patient 2. Since these two patients received
approximately 800 and 400 mg of iron from blood transfusions
during the period of deferoxamine therapy, they were estimated
to be in negative iron balance. This is confirmed by the decline
Each of the three children who received deferoxamine ther-
apy expressed at least one HLA antigen associated with idio-
pathic hemochromatosis; patient one and two each expressed
B7 while patient three expressed A3 and B14. In North Ameri-
can Caucasians, the antigen frequency of A3 is 26.0%, B7
18.7%, and B14 9.5% [20].
Side effects of defrroxamine therapy
No patient experienced side effects of deferoxamine therapy.
Serum levels of copper and zinc were not reduced following
therapy. Serum aluminum levels were less than 20 nglml before
and after therapy.
Discussion
Some children with chronic renal failure are unlikely to
receive a kidney transplant due to very high levels of preformed
HLA antibodies. Such children have a substantial risk for
complications of chronic iron intoxication due to repeated
blood transfusions. Iron overload may then cause significant
morbidity and mortality due to hepatic, cardiac and endocrine
dysfunction [1—5]. Deferoxamine therapy in children with tha-
lassemia major may prevent and even reverse some of the
complications of chronic iron intoxications [9, 10]. Following
deferoxamine therapy, the iron deferoxamine complex can be
excreted in the urine following glomerular filtration and in the
gastrointestinal tract following biliary excretion [21]. In adults
with chronic renal failure, intravenous deferoxamine during
hemodialysis and CAPD and intraperitoneal deferoxamine dur-
ing CAPD has been found to result in increased iron removal in
dialysate [Il, 12].
We treated three children with chronic iron overload with
intraperitoneal det'eroxamine therapy. Urinary excretion did
not occur as each child was anuric, however substantial
amounts of iron were removed in peritoneal dialysate during
deferoxamine therapy. Although not measured in this study,
biliary excretion of the iron deferoxamine complex can also
result in iron losses via the gastrointestinal tract [21]. When
considering only peritoneal dialysate iron removal, two of the
three children were estimated to be in negative iron balance
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Table 1. Laboratory values in each patient before, during and after intraperitoneal deferoxamine therapy
Patient
Iron
isg/dl
TIBC
ng/mI
(% saturation)
Ferritin
ng/ml
Liver density
Hounsfield
units
Mean dialysate iron content
g/24 hour, (range)
I pre
during
post
210
431—629
214
222 (94%)
225 (84%)
4163
2809—3786
2634
56.2
59.0
65.6
less than 10
5652 (3085—8045)
2 pre
during
post
174
211—330
169
195 (89%)
234 (72%)
2114
1266—1502
1192
58,3
69.0
less than 10
2241 (1912—2852)
3 pre
during
post
147
346—427
166
183 (80%)
231 (71%)
3049
2385—3318
2952
52.6
70.9
less than 10
4028 (2910—5583)
during the period of deferoxamine therapy. In these two chil-
dren, the serum ferritin level fell in conjunction with iron
removal. Due to multiple blood transfusions, the third patient
was estimated to be in positive iron balance and his serum
ferritin level did not decline.
Interestingly, the liver density in each child increased during
therapy regardless of estimated iron balance and the change in
the serum ferritin level, suggesting that liver iron content was
not reduced by therapy. There are several potential reasons for
this. First, the liver density as measured by computerized
tomography scanning may not reflect liver iron content in the
children. Since this technique to measure iron content has been
validated by other investigators [17, 18], and since we found a
linear correlation between the serum ferritin level and the
hepatic density among 10 children with renal failure, we feel
that the liver iron content was probably not reduced with
therapy. Second, iron storage in our patients may be primarily
in the reticuloendothelial system while deferoxamine removes
iron predominently from the parenchymal storage compartment
[22]. Thirdly, the moderately low dose of deferoxamine that we
used may not have been adequate to remove iron from the liver.
Utilizing higher doses of deferoxamine would possibly have
resulted in greater iron losses, negative iron balance in all of the
children studied, and perhaps a decline in liver density. Indeed,
a recent study of prolonged, high dose deferoxamine therapy
(40 mg/kg over the last 2 hours of dialysis for 13 to 42 months)
in four patients undergoing hemodialysis found that liver iron
content (measured by a y-ray scattering technique) decreased
significantly as did serum ferritin levels [23]. However, in
another study of children undergoing hemodialysis, deferoxa-
mine therapy (25 mg/kg) was not thought to be effective, and in
the individual patient changes in the serum ferritin level corre-
lated best with the amount of blood transfused [24].
Early studies in children with thalassemia receiving defero-
xamine by intramuscular injection demonstrated that hepatic
iron content increased over time in several children [25].
However, the increase in hepatic iron content was significantly
less in children receiving deferoxamine therapy compared to
children who were not treated with deferoxamine. Hepatic
fibrosis progressed in non-treated children while it remained
stable in deferoxamine treated children. Recently, high dose,
subcutaneous deferoxamine therapy in children with thalasse-
mia was found to result in reduced liver iron content in nearly
all children, but improvement in the histologic pattern of
fibrosis was rare and hepatic necrosis when present was not
eliminated [26]. These studies suggest that deferoxamine ther-
apy lessens but may not entirely prevent iron-induced liver
damage [25—27].
Although our patients suffered no side effects of deferoxa-
mine therapy, we chose not to give higher doses. Extensive
experience with deferoxamine therapy in children with thalas-
semia has lead to recognition of a number of side effects [28—
32]. Visual and auditory neurotoxicity manifested as decreased
visual acuity, loss of color vision, delayed visual evoked
potentials and high frequency sensorineural hearing loss was
more common in patients treated with high dose deferoxamine
compared to those receiving lower doses [32]. Since deferoxa-
mine excretion occurs primarily through glomerular filtration,
moderate or high dose therapy would likely result in toxicity in
patients with renal failure. In addition, several cases of fatal
Rhizopus infections have been observed in patients with renal
failure receiving deferoxamine [33, 34].
Several patients with chronic renal failure have developed
bullous cutaneous skin lesions typical of porphyria cutanea
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Fig. 2. Among the JO children who underwent a liver CT scan, there
was a linear correlation (r = 0.855; P <0.01) between the serum ferritin
and the liver density, suggesting that an increased serum ferritin level
correlation with elevated hepatic iron content.
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tarda. Some have normal plasma porphyrin profiles while
others demonstrate marked elevated plasma porphyrin levels as
did our patient [14, 16]. Since iron overload is thought to play a
role in the development of dialysis related porphyria cutanea
tarda, deferoxamine therapy might be beneficial. In our adoles-
cent with dialysis-related porphyria cutanea tards, deferoxa-
mine therapy resulted in dramatic improvement in the skin
lesions which reoccurred when deferoxamine therapy was
stopped and again resolved when therapy was reinstituted. This
response to deferoxamine therapy was also observed in another
patient with dialysis-related porphyria cutanea tarda who was
undergoing hemodialysis [16].
It is interesting that each of the three children in this study
expressed at least one HLA antigen associated with idiopathic
hemochromatosis. Although this finding may be fortuitous,
previous studies have suggested that adults and children who
express such antigens have an increased risk to develop iron
overload in response to blood transfusions [5, 7, 8]. For reasons
that are unclear, the transfusion requirement fell substantially
during deferoxamine therapy in two of the three children.
Recently, deferoxamine therapy was found to decrease trans-
fusion requirements and increase the hematocrit in adults
maintained by hemodialysis [35]. The pathophysiologic mech-
anism for this is unknown but may be related to inhibition of
iron catalyzed production of the hydroxyl radical which may
result in lipid peroxidation of red blood cell membranes [35, 361,
although an effect due to aluminum removal could not be
discounted.
In conclusion, we found that intraperitoneal deferoxamine
therapy can result in substantial iron removal and estimated
negative iron balance when the transfusion requirement is not
high, but that negative iron balance may not be achievable with
low dose deferoxamine when the patient requires frequent
transfusions. We also found that the serum ferritin correlated
with hepatic density as measured by CT scan, but that defero-
xamine therapy did not result in a decrease in liver density and
presumably liver iron content in any of the patients studied,
regardless of iron balance or the serum ferritin level. Future
availability of human recombinant erythropoietin will hopefully
prevent chronic iron intoxication and eliminate the need for
deferoxamine therapy.
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